ID

37767

Descripción

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00964704

Link

https://clinicaltrials.gov/show/NCT00964704

Palabras clave

Versiones (1)
  1. 22/8/19 22/8/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

22 de agosto de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT00964704

Inglés

Eligibility Breast Cancer NCT00964704

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female patients, age >/=18 years
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
locally recurrent or metastatic her2-positive breast cancer
Descripción

HER2-positive carcinoma of breast Recurrent Locally | HER2-positive carcinoma of breast metastatic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1960398
UMLS CUI [1,2]
C2945760
UMLS CUI [1,3]
C1517927
UMLS CUI [2,1]
C1960398
UMLS CUI [2,2]
C1522484
disease progression during or up to 12 months after prior adjuvant therapy with trastuzumab
Descripción

Disease Progression During Adjuvant therapy | Disease Progression Post Adjuvant therapy | trastuzumab

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0242656
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C0677850
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C0677850
UMLS CUI [3]
C0728747
lvef >/=55% at baseline
Descripción

Left ventricular ejection fraction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428772
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with bevacizumab or capecitabine
Descripción

bevacizumab | capecitabine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0796392
UMLS CUI [2]
C0671970
anthracyclines in prior adjuvant or neoadjuvant treatment exceeding cumulative dose of 360mg/m2 for doxorubicin and 720mg/kg for epirubicin
Descripción

Anthracyclines Adjuvant therapy | Anthracyclines Neoadjuvant Therapy | Doxorubicin Cumulative Dose | Epirubicin Cumulative Dose

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0282564
UMLS CUI [1,2]
C0677850
UMLS CUI [2,1]
C0282564
UMLS CUI [2,2]
C0600558
UMLS CUI [3,1]
C0013089
UMLS CUI [3,2]
C2986497
UMLS CUI [4,1]
C0014582
UMLS CUI [4,2]
C2986497
chronic daily treatment with corticosteroids (>10mg/day methylprednisolone equivalent; excluding inhaled corticosteroids), or aspirin (>325mg/day), or clopidogrel (>75mg/day)
Descripción

Adrenal Cortex Hormones chronic U/day | Methylprednisolone Equivalent | Exception Adrenal Cortex Hormones by Inhalation | Aspirin U/day | Clopidogrel U/day

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0205191
UMLS CUI [1,3]
C0456683
UMLS CUI [2,1]
C0025815
UMLS CUI [2,2]
C0205163
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0001617
UMLS CUI [3,3]
C0205535
UMLS CUI [4,1]
C0004057
UMLS CUI [4,2]
C0456683
UMLS CUI [5,1]
C0070166
UMLS CUI [5,2]
C0456683
clinically significant cardiac disease, or cardiac toxicity during previous trastuzumab therapy
Descripción

Heart Disease | Cardiotoxicity During Prior Therapy | trastuzumab

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2,1]
C0876994
UMLS CUI [2,2]
C0347984
UMLS CUI [2,3]
C1514463
UMLS CUI [3]
C0728747
evidence of spinal cord compression or cns metastasis
Descripción

Compression of spinal cord | CNS metastases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0037926
UMLS CUI [2]
C0686377
history of other malignancy, unless disease-free for >/=5 years or treated curatively for carcinoma in situ of the cervix or non-melanomatous skin cancer
Descripción

Cancer Other | Exception Disease Free Duration | Exception Curative treatment Carcinoma in situ of uterine cervix | Exception Curative treatment Skin carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0012634
UMLS CUI [2,3]
C0332296
UMLS CUI [2,4]
C0449238
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C0851140
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1273390
UMLS CUI [4,3]
C0699893
Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT00964704

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
male or female patients, age >/=18 years
boolean
C0001779 (UMLS CUI [1])
HER2-positive carcinoma of breast Recurrent Locally | HER2-positive carcinoma of breast metastatic
Item
locally recurrent or metastatic her2-positive breast cancer
boolean
C1960398 (UMLS CUI [1,1])
C2945760 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C1960398 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
Disease Progression During Adjuvant therapy | Disease Progression Post Adjuvant therapy | trastuzumab
Item
disease progression during or up to 12 months after prior adjuvant therapy with trastuzumab
boolean
C0242656 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C0677850 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0677850 (UMLS CUI [2,3])
C0728747 (UMLS CUI [3])
Left ventricular ejection fraction
Item
lvef >/=55% at baseline
boolean
C0428772 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
bevacizumab | capecitabine
Item
prior treatment with bevacizumab or capecitabine
boolean
C0796392 (UMLS CUI [1])
C0671970 (UMLS CUI [2])
Anthracyclines Adjuvant therapy | Anthracyclines Neoadjuvant Therapy | Doxorubicin Cumulative Dose | Epirubicin Cumulative Dose
Item
anthracyclines in prior adjuvant or neoadjuvant treatment exceeding cumulative dose of 360mg/m2 for doxorubicin and 720mg/kg for epirubicin
boolean
C0282564 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
C0282564 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
C0013089 (UMLS CUI [3,1])
C2986497 (UMLS CUI [3,2])
C0014582 (UMLS CUI [4,1])
C2986497 (UMLS CUI [4,2])
Adrenal Cortex Hormones chronic U/day | Methylprednisolone Equivalent | Exception Adrenal Cortex Hormones by Inhalation | Aspirin U/day | Clopidogrel U/day
Item
chronic daily treatment with corticosteroids (>10mg/day methylprednisolone equivalent; excluding inhaled corticosteroids), or aspirin (>325mg/day), or clopidogrel (>75mg/day)
boolean
C0001617 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0025815 (UMLS CUI [2,1])
C0205163 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0001617 (UMLS CUI [3,2])
C0205535 (UMLS CUI [3,3])
C0004057 (UMLS CUI [4,1])
C0456683 (UMLS CUI [4,2])
C0070166 (UMLS CUI [5,1])
C0456683 (UMLS CUI [5,2])
Heart Disease | Cardiotoxicity During Prior Therapy | trastuzumab
Item
clinically significant cardiac disease, or cardiac toxicity during previous trastuzumab therapy
boolean
C0018799 (UMLS CUI [1])
C0876994 (UMLS CUI [2,1])
C0347984 (UMLS CUI [2,2])
C1514463 (UMLS CUI [2,3])
C0728747 (UMLS CUI [3])
Compression of spinal cord | CNS metastases
Item
evidence of spinal cord compression or cns metastasis
boolean
C0037926 (UMLS CUI [1])
C0686377 (UMLS CUI [2])
Cancer Other | Exception Disease Free Duration | Exception Curative treatment Carcinoma in situ of uterine cervix | Exception Curative treatment Skin carcinoma
Item
history of other malignancy, unless disease-free for >/=5 years or treated curatively for carcinoma in situ of the cervix or non-melanomatous skin cancer
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C0332296 (UMLS CUI [2,3])
C0449238 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C0851140 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C1273390 (UMLS CUI [4,2])
C0699893 (UMLS CUI [4,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial